Abstract:To minimize premature release of drugs from their carriers during circulation in the blood stream, we have recently developed reversible disulfide cross-linked micelles (DCMs) that can be triggered to release drug at the tumor site or in cancer cells. We designed and synthesized thiolated linear-dendritic polymers (telodendrimers) by introducing cysteines to the dendritic oligo-lysine backbone of our previously reported telodendrimers comprised of linear polyethylene glycol (PEG) and a dendritic cluster of cholic acids. Reversibly cross-linked micelles were then prepared by the oxidization of thiol groups to disulfide bond in the core of micelles after the self-assembly of thiolated telodendrimers. The DCMs were spherical with a uniform size of 28 nm, and were able to load paclitaxel (PTX) in the core with superior loading capacity up to 35.5% (w/w, drug/micelle). Cross-linking of the micelles within the core reduced their apparent critical micelle concentration and greatly enhanced their stability in non-reductive physiological conditions as well as severe micelle-disrupting conditions. The release of PTX from the DCMs was significantly slower than that from non-cross-linked micelles (NCMs), but can be gradually facilitated by increasing the concentration of reducing agent (glutathione) to an intracellular reductive level. The DCMs demonstrated a longer in vivo blood circulation time, less hemolytic activities, and superior toxicity profiles in nude mice, when compared to NCMs. DCMs were found to be able to preferentially accumulate at the tumor site in nude mice bearing SKOV-3 ovarian cancer xenograft. We also demonstrated that the disulfide cross-linked micellar formulation of PTX (PTX-DCMs) was more efficacious than both free drug and the non-cross-linked formulation of PTX at equivalent doses of PTX in the ovarian cancer xenograft mouse model. The anti-tumor effect of PTX-DCMs can be further enhanced by triggering the release of PTX on-demand by the administration of the FDA approved reducing agent, N-acetylcysteine, after PTX-DCMs have reached the tumor site.

Disulfide Cross-Linked Micelles for the Targeted Delivery of Vincristine to B-cell Lymphoma.

[Transdermal and Lymph Targeting Transfersomes of Vincristine].

Nonspecifically Enhanced Therapeutic Effects of Vincristine on Multidrug-Resistant Cancers when Coencapsulated with Quinine in Liposomes

Biodegradable Self-Assembled Micelles Based on MPEG-PTMC Copolymers: An Ideal Drug Delivery System for Vincristine

Lymph Cancer Chemotherapy: Delivery Of Doxorubicin-Gemcitabine Prodrug And Vincristine By Nanostructured Lipid Carriers

Reversibly Disulfide Cross-Linked Micelles Improve The Pharmacokinetics And Facilitate The Targeted, On-Demand Delivery Of Doxorubicin In The Treatment Of B-Cell Lymphoma

Targeted Killing of Cancer Cells in Vivo and in Vitro with IGF-IR Antibody-Directed Carbon Nanohorns Based Drug Delivery

A Novel Submicron Emulsion System Loaded with Vincristine–oleic Acid Ion-Pair Complex with Improved Anticancer Effect: in Vitro and in Vivo Studies

Exogenous Vitamin C Triggered Structural Changes of Redox-Activated Dual Core-Crosslinked Biodegradable Nanogels for Boosting the Antitumor Efficiency

Development of a stable single-vial liposomal formulation for vincristine

Dual Agent Loaded PLGA Nanoparticles Enhanced Antitumor Activity in a Multidrug-Resistant Breast Tumor Eenograft Model

Well-defined, reversible disulfide cross-linked micelles for on-demand paclitaxel delivery.

Targeted Sustained Delivery of Antineoplastic Agent with Multicomponent Polylactide Stereocomplex Micelle.

Application of functional vincristine plus dasatinib liposomes to deletion of vasculogenic mimicry channels in triple-negative breast cancer

Vincristine-doxorubicin co-loaded artificial low-density lipoproteins towards solid tumours

Hyaluronic Acid-Coated Cationic Nanostructured Lipid Carriers for Oral Vincristine Sulfate Delivery

Exogenous vitamin C boosts the antitumor efficacy of paclitaxel containing reduction-sensitive shell-sheddable micelles in vivo

Vincristine and temozolomide combined chemotherapy for the treatment of glioma: a comparison of solid lipid nanoparticles and nanostructured lipid carriers for dual drugs delivery

Advances in the study of vincristine: an anticancer ingredient from Catharanthus roseus]

Self-crosslinkable and Intracellularly Decrosslinkable Biodegradable Micellar Nanoparticles: A Robust, Simple and Multifunctional Nanoplatform for High-Efficiency Targeted Cancer Chemotherapy.

Tumor Targeting of Vincristine by Mbaff-Modified PEG Liposomes in B Lymphoma Cells.